BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20804567)

  • 1. The Met oncogene and basal-like breast cancer: another culprit to watch out for?
    Gastaldi S; Comoglio PM; Trusolino L
    Breast Cancer Res; 2010; 12(4):208. PubMed ID: 20804567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal breast cancer: a complex and deadly molecular subtype.
    Bertucci F; Finetti P; Birnbaum D
    Curr Mol Med; 2012 Jan; 12(1):96-110. PubMed ID: 22082486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.
    Toft DJ; Cryns VL
    Mol Endocrinol; 2011 Feb; 25(2):199-211. PubMed ID: 20861225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.
    Gastaldi S; Sassi F; Accornero P; Torti D; Galimi F; Migliardi G; Molyneux G; Perera T; Comoglio PM; Boccaccio C; Smalley MJ; Bertotti A; Trusolino L
    Oncogene; 2013 Mar; 32(11):1428-40. PubMed ID: 22562252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer.
    Alam MS; Sultana A; Sun H; Wu J; Guo F; Li Q; Ren H; Hao Z; Zhang Y; Wang G
    Front Pharmacol; 2022; 13():942126. PubMed ID: 36204232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Interaction of
    Zoungrana LI; Krause-Hauch M; Wang H; Fatmi MK; Bates L; Li Z; Kulkarni P; Ren D; Li J
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy.
    Hussain Y; Khan H; Alam W; Aschner M; Abdullah ; Alsharif KF; Saso L
    Oxid Med Cell Longev; 2022; 2022():4831833. PubMed ID: 35795855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.
    Alam MS; Sultana A; Reza MS; Amanullah M; Kabir SR; Mollah MNH
    PLoS One; 2022; 17(5):e0268967. PubMed ID: 35617355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistics and network-based approaches to identify molecular mechanisms that drive the progression of breast cancer.
    Alam MS; Rahaman MM; Sultana A; Wang G; Mollah MNH
    Comput Biol Med; 2022 Jun; 145():105508. PubMed ID: 35447458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma.
    Zhang S; Wang Y; Cao Y; Wu J; Zhang Z; Ren H; Xu X; Kaznacheyeva E; Li Q; Wang G
    Front Pharmacol; 2022; 13():851832. PubMed ID: 35370635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Network Pharmacology and Cytology Experiments to Identify Potential Anti-Breast Cancer Targets and Mechanisms of Delphinidin.
    Peng J; Wu A; Yu X; Zhong Q; Deng X; Zhu Y
    Nutr Cancer; 2022; 74(7):2591-2606. PubMed ID: 34875956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells.
    Omeljaniuk WJ; Krętowski R; Ratajczak-Wrona W; Jabłońska E; Cechowska-Pasko M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
    Wang Z; Hu S; Li X; Liu Z; Han D; Wang Y; Wei L; Zhang G; Wang X
    BMC Cancer; 2021 Nov; 21(1):1188. PubMed ID: 34743685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis.
    Zeng X; Shi G; He Q; Zhu P
    Sci Rep; 2021 Oct; 11(1):20799. PubMed ID: 34675265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
    Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S
    Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses.
    Xiao X; Zhang Z; Luo R; Peng R; Sun Y; Wang J; Chen X
    Oncol Lett; 2021 May; 21(5):363. PubMed ID: 33747220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation biomarkers for nasopharyngeal carcinoma.
    Han B; Yang X; Zhang P; Zhang Y; Tu Y; He Z; Li Y; Yuan J; Dong Y; Hosseini DK; Zhou T; Sun H
    PLoS One; 2020; 15(4):e0230524. PubMed ID: 32271791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of Prognostic Factors in Early-Onset Breast Cancer.
    Yu Z; He Q; Xu G
    Technol Cancer Res Treat; 2020; 19():1533033819893670. PubMed ID: 32028860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Recent Developments and Progress in Computational Drug Repositioning.
    Shi W; Chen X; Deng L
    Curr Pharm Des; 2020; 26(26):3059-3068. PubMed ID: 31951162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance.
    Hermawan A; Putri H; Utomo RY
    Mol Divers; 2020 Nov; 24(4):933-947. PubMed ID: 31659695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.